What Happened

In June 2024, the U.S. Department of Justice indicted Done Global Inc. / Done Health P.C. founder and CEO Ruthia. He and clinical president David Brody for a $100 million scheme involving the dispensing of Adderall and other stimulants without a legitimate medical purpose. The indictment alleged that the subscription-based telehealth platform targeted drug seekers, submitted fraudulent insurance prior-authorizations, and obstructed the federal investigation.

The scheme allegedly caused the dispensing of millions of doses of stimulants through a business model in which patients paid subscription fees for rapid, low-scrutiny prescriptions. Both defendants were ultimately convicted at trial; He was later sentenced to six years in prison and a $1 million fine, and Brody was sentenced to 24 months, in connection with the roughly $90 million scheme.

Unlike the clinical diversion cases on this site, this case is a supply-side scheme: the controlled substances were obtained through prescriptions rather than from hospital stock, and the alleged harm flowed from how the prescriptions were generated, not how the drugs were stored.

What Went Wrong

Analysis of the alleged scheme points to failures of clinical gatekeeping and corporate oversight:

  • The subscription business model created a financial incentive to issue prescriptions quickly, with revenue tied to patient volume rather than to clinical appropriateness.
  • Prescribers appear to have lacked effective, independent review of whether each prescription served a legitimate medical purpose, the core legal requirement for a controlled substance prescription.
  • No meaningful red-flag screening identified drug-seeking patients, and the platform allegedly targeted them rather than referring them to appropriate care.
  • Fraudulent insurance prior-authorizations were allegedly submitted, indicating that billing and documentation controls were absent or overridden.
  • Alleged obstruction of the federal investigation suggests there was no functioning compliance function willing to cooperate with regulators once concerns arose.

How It Could Have Been Prevented

  • Require documented evidence of a legitimate medical purpose for every controlled substance prescription, with independent clinical review of high-volume or high-risk prescribers.
  • Screen patients and prescribers against red-flag indicators, including drug-seeking patterns, and audit prescription volume and demographics continuously.
  • Separate the revenue function from the clinical decision function so that subscription or visit volume cannot influence prescribing decisions.
  • Implement compliance controls over prior-authorization submissions, with audit trails and routine verification of submitted claims.
  • Maintain a functioning compliance program with documented cooperation obligations, and monitor prescriber outliers against internal benchmarks.

Related Guidance

Sources